Share: Facebook Twitter LinkedIn
Activity Provided By:

Physicians’ Education Resource®, LLC

Exploring the Advent of Antibody-Drug Conjugates Across Multiple Tumor Types: Implications for Testing and Treatment Planning

Access Activity

Overview / Abstract:

Target Audience
This educational program is directed toward the American Society of Clinical Oncology (ASCO) audience, including medical oncologists, pathologists, radiation oncologists, and surgical oncologists. Other attendees of the ASCO Annual Meeting who have an interest in the treatment of cancer, such as nurses, physician assistants, fellows, and residents, are also invited to participate.

Program Overview
This online, on-demand virtual symposium brings together renowned experts in a variety of tumor types to help physicians assess the latest available data on antibody-drug conjugates that target HER2/3 overexpression in breast, gastrointestinal (GI), and lung cancers. In this educational program, these experts discuss the mechanism of action, novel testing strategies and applications, as well as emerging data for HER2, HER3, and Trop2 antibody-drug conjugate treatment approaches across cancer care. They also review treatment challenges, highlight emerging data, and forecast areas of future research and treatment options that address real-world clinical challenges.

This educational activity is an archive of the live virtual symposium held on June 4, 2021.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Determine the rationale underlying the use of antibody-drug conjugates in solid tumors
Apply optimized HER2-testing strategies to facilitate molecular characterization of patients with solid tumors
Discuss ongoing clinical trials and evolving data sets assessing safety and efficacy of novel antibody-drug conjugates in the management of patients with solid tumors
Devise strategies to integrate novel antibody-drug conjugate approaches into clinical practice for management of patients with a variety of solid tumors

Expiration

Jun 15, 2022

Discipline(s)

Physician CME

Format

Online

Credits / Hours

2.0

Accreditation

ACCME

Presenters / Authors / Faculty

Sara A. Hurvitz, MD, FACP
Paul A. Bunn Jr, MD
Ryan B. Corcoran, MD, PhD
Yelena Y. Janjigian, MD

Sponsors / Supporters / Grant Providers

AstraZeneca and Daiichi Sankyo, Inc.

Keywords / Search Terms

Relias LLC Relias, Free CME, Tumors, Antibody-Drug Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map